|
| Clinical observation of Cinobufacini injection combined with TACE in the treatment of hepatocellular carcinoma |
| Hits 1628 Download times 1865 Received:December 30, 2014 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2015.05.06 |
| Key Words
Cinobufacini injection;TACE;hepatocellular carcinoma;observation of efficacy |
| Author Name | Affiliation | | DENG Zhen-yun | The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China | | DUAN Hao-bo | Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China |
|
| Abstract
|
| [Objective] To define the safety and effect of combination of Cinobufacini injection and transcatheter arterial chemoembolization(TACE) in patients with hepatocellular carcinoma. [Methods] The 53 cases of hepatocellular carcinoma were selected and randomly assigned into control group and treatment group. Patients of control group(27 cases) received TACE treatment only, while others of treatment group(26 cases) received Cinobufacini injection as well as TACE treatment. The AFP, objective tumor size, quality of life score, symptom score of traditional Chinese medicine and toxicity were assessed. [Results] Two cases were removed in control group and treatment group excluded one case. In treatment group AFP decreased significantly than control group (P<0.05). Disease control rate was 88.00%(22/25) in treatment group and 79.17%(19/24)in control group, which showed significant difference between two groups(P<0.05). Quality of life score and symptom score of traditional Chinese medicine were improved and showed better results in treatment group than those observed in control group(P<0.05). The incidence of liver toxicity, marrow suppression and gastrointestinal reaction was significantly lower than that in the control group(P<0.05). [Conclusion] The combination of Cinobufacini injection and TACE in treatment of hepatocellular carcinoma can significantly decrease AFP, improve disease control rate, relieve clinical symptoms, improve life quality of patients and reduce the incidence of adverse reactions. |
|
|
|
|
|
|
|
